Traders Watching Regeneron (REGN) Following Amgen (AMGN) AMG 145 Results
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Join SI Premium – FREE
Amgen (Nasdaq: AMGN) shares are ticking higher Monday morning following strong data from a Phase 1b clinical study of AMG 145. Shares are up about 1.7 percent ahead of the bell.
Earlier, Amgen reported that "The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001)."
Traders are keeping their sights on Regeneron (Nasdaq: REGN), Dendreon (Nasdaq: DNDN), Affymax (Nasdaq: AFFY), and BioGen (Nasdaq: BIIB).
Earlier, Amgen reported that "The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001)."
Traders are keeping their sights on Regeneron (Nasdaq: REGN), Dendreon (Nasdaq: DNDN), Affymax (Nasdaq: AFFY), and BioGen (Nasdaq: BIIB).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kenon Holdings (KEN) halted, news pending
- Goldman Sachs to acquire Neos in $2.3B deal
- Delta Probing Unauthorized Wi-Fi on Flight After Hacker Event - Bloomberg
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
